Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris

TWIN Achieved Primary and Secondary Efficacy Endpoints with Statistical Significance and a Favorable Tolerability Profile
Subject to End of Phase 2 Meeting to be Scheduled with the FDA, Commencement of Phase 3 Program Planned for 2018
Further Validation of Sol-Gel’s Silica-based Encapsulation Platform Technology